A Case of Pneumonia under Belatacept and Everolimus: Benefit-Risk Balance between Renal Allograft Function and Infection.

pneumonia is an opportunistic disease usually prevented by trimethoprim-sulfamethoxazole. A 49-year-old HLA-sensitized male with successful late conversion from tacrolimus-based to belatacept-based immunosuppression developed pneumonia for which he presented several risks factors: low lymphocyte count with no CD4+ T cells detected since 2 years, hypogammaglobulinemia, history of acute cellular rejection 3 years before, and immunosuppressive treatment (belatacept, everolimus). Because of respiratory gravity in the acute phase, the patient was given oxygen, corticosteroids, and trimethoprim-sulfamethoxazole.

[Assessment of iron deficiency anemia management in the general hospital of Grenoble: A 12-month follow-up of an intravenous ferric carboxymaltose treatment program in a cohort of patients with non-dialysis-dependent chronic kidney disease].

Introduction: The FIND-CKD study has validated the use of ferric carboxymaltose (FCM) injection with a target of ferritin level between 400 and 600ng/mL to treat iron deficiency anemia in non-dialysis-dependent chronic kidney disease (ND-CKD) patients. In order to assess this strategy in clinical practice, we constituted a cohort of patients within our nephrology department.

Patients And Methods: Patients had CKD stages 3 to 5, hemoglobin level (Hb)<13g/dL (men) or<12g/dL (women), and ferritin level (F)<100ng/mL or transferrin saturation (TSAT)<20%.

Identification of drug-related problems in ambulatory chronic kidney disease patients: a 6-month prospective study.

Background: Drug-related problems (DRPs) are common in chronic kidney disease (CKD) patients. We developed a 2-step consultation including a clinical pharmacist (CP) session and a nephrologist conventional care consultation to explore the feasibility of a pilot drug-oriented disease management program in controlling iatrogenic side effects.

Methods: Drug inventory was estimated by a CP before each nephrology consultation.

Pharmaceutical care in chronic kidney disease: experience at Grenoble University Hospital from 2006 to 2010.

Background: Clinical pharmacists (CPs) specifically manage lab-test follow-up, adapt drug dosage according to guidelines and evaluate cardiovascular risk factors and decline in renal function. The aim of this study was to assess the impact of clinical pharmacy services in outpatient nephrology clinics.

Method: For each patient, medical history and current treatment were obtained.

Assessing a pharmacist-run anaemia educational programme for patients with chronic renal insufficiency.

Objective: Assessment of a pharmacist-run anaemia educational programme for patients with chronic renal insufficiency.

Setting: Nephrology Department, Grenoble Hospital, France.

Method: A 12-week prospective study, using a before-after intervention design.